mAb Programs Supported
1 +
BLA / MAA Submissions
1 +

IND–BLA

Complete CMC Lifecycle

ICH

Q6B · Q5E · Q8 · Q11

mAb CMC Consulting Comprehensive
Support Across the
mAb Development
Lifecycle

DES Pharma supports monoclonal antibody programs across full-length IgG molecules, engineered antibody variants, fragments, bispecific formats, and related recombinant antibody products.

Our teams understand how early choices around isotype, expression system, and product profile influence manufacturability, analytical strategy, and long-term development planning. We help clients build practical CMC paths around common mAb platforms, including CHO-based production, clone selection, upstream optimization, downstream purification, and phase-appropriate formulation planning.

mAb Platform Expertise

Formats, expression systems & CQA strategy

Formats & Modalities
Expression & Platform
Critical Quality Attributes

What We DomAb Services Across the Development Continuum

From cell line development through commercial readiness, our consultants work inside your CMC team to
keep timelines moving and regulatory packages strong.

Program & Process Development

End-to-end mAb process development support, from expression system selection through commercial-scale process characterization and validation readiness.

Analytical Development & QC

Specialized mAb characterization and analytical method development aligned with ICH Q6B specifications and phase-appropriate regulatory expectations.

Supply Chain & Procurement

Strategic supply chain planning for mAb manufacturing, ensuring material availability, CDMO alignment, and cold-chain integrity across clinical and commercial programs.

Quality Assurance

mAb-focused GMP quality support aligned with FDA biologics expectations and ICH Q5E comparability requirements, from Phase 1 through commercial lifecycle management.

Phase-Appropriate Support Where Are You in Your mAb
Program?

We calibrate our CMC consulting to your development stage, from the first IND-enabling study to post-approval lifecycle management.

Pre-Clinical / IND-Enabling

CMC strategy for your first-in-human submission, covering process definition, initial characterization, and IND-ready documentation.

Phase 1–2 Clinical

Finalize your manufacturing process, expand analytical characterization, and build a robust CMC package for IND amendments and dose escalation.

Phase 2 Pivotal / Phase 3

Prepare your PPQ briefing book, finalize commercial process, and build comparability packages for any process changes implemented since Phase 1.

BLA / Commercial Filing

CMC authoring, BLA Module 3 assembly, and post-approval lifecycle planning for commercial mAb programs.

Ongoing Lifecycle & Post-Approval

Manufacturing site changes, analytical method transfers, and post-approval comparability exercises require technically rigorous CMC packages. We support sponsors navigating these changes efficiently.

Our mAb Expertise Deep Technical Knowledge Across the mAb Platform

DES Pharma’s mAb practice is built around the quality attributes and manufacturing decisions that determine whether a program succeeds at scale. For most molecules, that means .building control strategies around aggregation, charge heterogeneity, glycosylation patterns, sequence variants, potency, and stability, connecting those attributes to the upstream and downstream process choices that drive them. We work across CHO cell culture platforms, Protein A chromatography strategies, and downstream polishing approaches to ensure that process development decisions are traceable to product quality outcomes.

Our analytical support uses methods including SEC-MALS for aggregation, icIEF for charge variant profiling, glycan mapping for Fc-related quality attributes, and potency assays calibrated to the product mechanism and development stage. Characterization work is structured against ICH Q6B expectations for biotechnological products, with comparability planning aligned to ICH Q5E and viral safety documentation aligned to ICH Q5A where applicable.

We help sponsors build technically sound, phase-appropriate CMC packages from IND-enabling work through commercial readiness, including FDA BLA support, post-approval change management, and lifecycle planning when manufacturing, testing, or site strategy evolves.

Upstream Process Development

CHO cell line development, fed-batch optimization, dissolved oxygen control, temperature shift strategies, and bioreactor scale-up design for mAb titer and quality.

Downstream Purification

Protein A affinity capture, viral clearance design, polishing by ion exchange and HIC, UF/DF optimization, and step yield / impurity clearance characterization.

Analytical Characterization

Comprehensive characterization per ICH Q6B: peptide mapping, glycan analysis, charge variants, aggregation, potency, and higher-order structure to support specifications and CQA risk assessment.

Comparability & Lifecycle

ICH Q5E-aligned comparability studies for process changes, site transfers, and scale-up events, with documentation strategies designed to support BLA supplements and MAA variations.

BLA-Ready CMC Documentation

Module 3 authoring, specification package development, PPQ reporting, and pre-BLA meeting preparation calibrated to FDA CDER/CBER expectations for licensed biologics.

Why DES Pharma What Sets Our mAb Practice Apart

Our consultants bring hands-on experience from mAb development programs across multiple platforms, sponsors, and CDMOs, so we know where programs get stuck and how to keep them moving.

Platform-Specific Technical Depth

Our team understands CHO biology, Protein A chromatography, aggregation kinetics, and mAb glycosylation in a way that generalist consultants cannot replicate. We bring modality-specific judgment to every engagement.

Regulatory-First Documentation

Every CMC deliverable is built with the reviewer in mind. We write IND sections, BLA modules, and briefing books that anticipate agency questions and reduce information request cycles.

Process–Analytical Integration

We connect your upstream and downstream development work directly to your analytical characterization and control strategy, ensuring CQAs are understood mechanistically, not just measured.

Phase-Appropriate Efficiency

We resist the temptation to over-engineer early-stage programs. Our recommendations are calibrated to development stage, helping you invest development resources where they create the most value.

CDMO Navigation & Oversight

We know how CDMOs work: their capabilities, constraints, and communication styles. We help you select the right manufacturing partners and maintain technical oversight throughout the relationship.

Lifecycle & Change Management

mAb programs evolve. We support comparability exercises, site change management, and post-approval variations with the scientific rigor and documentation quality regulators expect.

Our Approach How We Engage on mAb Programs

We begin by understanding your program’s specific context (molecule, stage, regulatory history, and team) before recommending a CMC strategy. Our engagements are structured, transparent, and aligned to
deliverables that move your program forward.

Program Assessment & Gap Analysis

We review your existing CMC documentation, process data, and analytical package to identify gaps relative to phase-appropriate expectations and your target regulatory pathway (BLA, MAA, or hybrid).

CMC Strategy Development

We define a fit-for-purpose CMC roadmap covering process development milestones, analytical method plan, specification development strategy, and regulatory filing timeline — integrated with your clinical plan.

Technical Execution & Oversight

Our consultants can lead, support, or oversee specific workstreams, from writing study protocols and directing CDMO activities to reviewing analytical data and authoring CMC sections in real time.

Regulatory Submission Support

We prepare, review, and respond to IND submissions, IND amendments, BLA modules, and agency meeting packages, with the documentation quality that reflects positively on your program.

Regulatory References

ICH Q6B

Specifications for Biotechnological & Biological Products: anchor for mAb characterization and specification strategy.

ICH Q5E

Comparability of Biotechnological Products: governs manufacturing change and site transfer strategy.

ICH Q8

Pharmaceutical Development: underpins design space and process understanding documentation.

ICH Q11

Development and Manufacture of Drug Substances: covers process selection and control strategy for biologics.

FDA Guidance

FDA Development of Therapeutic Protein Biosimilars: relevant for lifecycle and comparability-heavy mAb programs.

Get Started Ready to Strengthen Your mAb CMC Strategy?

Whether you’re preparing your first IND or finalizing a BLA submission, our consultants are ready to assess your
program and identify the highest-value areas for support.